No Data
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $16
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Chordia Research Memo (2): Spun out from takeda pharmaceuticals sp adr, focusing on the development of anticancer drugs.
■Company overview of Chordia Therapeutics <190A> 1. Company history The company is a bioventure established in October 2017 by six drug discovery researchers who spun out from takeda pharmaceuticals sp adr, where they were involved in the development of low molecular weight compound anticancer drugs. Four products were selected from the pipeline that was being developed during the takeda pharmaceuticals sp adr era, and a licensing agreement regarding exclusive research, development, manufacturing, and sales was signed with takeda pharmaceuticals sp adr in November of the same year.
Chordia---a biotech venture advancing the development of anticancer drugs that could become block inc.
Chordia Therapeutics <190A> is a biotech venture founded by drug discovery researchers who spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of low molecular weight anti-cancer drugs. The core business ranges from exploratory research to clinical research, and domestically, it conducts manufacturing and sales on its own through a partnership strategy, aiming for early monetization by licensing out overseas. It was listed on the Tokyo Stock Exchange Growth Market in June 2024.
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
US Manufacturing Index Rises To 43, Highest Since 2020
No Data
No Data
